Related Experiment Video

Updated: Aug 14, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Dual inhibition of HSF1 and DYRK2 impedes cancer progression

Vasudha Tandon1, Rita Moreno1, Kira Allmeroth2

  • 1Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee DD1 9SY, U.K.

Bioscience Reports
|January 9, 2023
PubMed

Insights

Targeting the DYRK2-HSF1 axis in cancer halts tumor growth and overcomes resistance. This dual inhibition induces apoptosis faster than single-target approaches, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells rely on proteostasis for survival.
  • DYRK2 kinase activates heat-shock factor 1 (HSF1) and the 26S proteasome.
  • Targeting DYRK2 is a viable strategy for proteotoxic stress-sensitive cancers.

Purpose of the Study:

  • To investigate the efficacy of concurrently targeting DYRK2 and HSF1.
  • To determine if combined inhibition is superior to targeting either molecule alone.
  • To evaluate the therapeutic potential of the DYRK2-HSF1 axis in cancer treatment.

Main Methods:

  • Utilized KRIBB11, a direct HSF1 inhibitor.
  • Conducted experiments involving concurrent targeting of DYRK2 and HSF1.
  • Assessed cancer cell apoptosis and tumor burden in xenograft models.

Main Results:

  • Concurrent targeting of DYRK2 and HSF1 induced apoptosis more rapidly than individual targeting.
  • The DYRK2-HSF1 axis inhibition led to cell death in proteasome inhibitor-resistant cells.
  • Combined inhibition reduced triple-negative breast cancer (TNBC) burden in vivo.

Conclusions:

  • Cotargeting DYRK2 and HSF1 is a promising strategy against neoplastic malignancies.
  • This dual-targeting approach can overcome resistance mechanisms.
  • The DYRK2-HSF1 axis represents a druggable target for cancer therapy.
Keywords:
inhibitionmyelomaproteasomesstress kinases

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K